Recent Analysts’ Ratings Changes for Illumina (ILMN)

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

• 9/9/2026 – Illumina was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $260.00 price target on the stock, up from $135.00.
• 9/3/2026 – Illumina had its price target raised by Argus from $180.00 to $235.00. They now have a “buy” rating on the stock.
• 9/1/2026 – Illumina was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/31/2026 – Illumina had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/5/2026 – Illumina was downgraded by Deutsche Bank Aktiengesellschaft to “hold”.
• 8/3/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $190.00 to $205.00. They now have a “hold” rating on the stock.
• 8/3/2026 – Illumina had its price target raised by Citigroup Inc. from $95.00 to $113.00. They now have a “sell” rating on the stock.
• 8/3/2026 – Illumina was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/3/2026 – Illumina had its “overweight” rating reaffirmed by Piper Sandler. They now have a $225.00 price target on the stock, up from $200.00.
• 8/1/2026 – Illumina was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/31/2026 – Illumina had its price target raised by Royal Bank Of Canada from $170.00 to $230.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Illumina had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $215.00 price target on the stock.
• 7/31/2026 – Illumina had its price target raised by Guggenheim from $200.00 to $226.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by Barclays PLC from $145.00 to $160.00. They now have an “underweight” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by JPMorgan Chase & Co. from $220.00 to $230.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by TD Cowen from $192.00 to $210.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Illumina had its price target raised by Stifel Nicolaus from $155.00 to $225.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,062,465 shares of company stock worth $436,589,802 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.